menu
    • menu
    [{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SPX-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SparX Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SparX Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SparX Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Arovella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"SPX-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SparX Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SparX Biopharmaceutical \/ Arovella Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"SparX Biopharmaceutical \/ Arovella Therapeutics"},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPX-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SparX Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SparX Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SparX Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPX-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SparX Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SparX Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SparX Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SPX-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SparX Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SparX Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SparX Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Mitsubishi Tanabe Pharma America","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"SparX Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SparX Biopharmaceutical \/ Mitsubishi Tanabe Pharma America","highestDevelopmentStatusID":"1","companyTruncated":"SparX Biopharmaceutical \/ Mitsubishi Tanabe Pharma America"}]

    Find Clinical Drug Pipeline Developments & Deals by SparX Biopharmaceutical

    Menu

    SparX Biopharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SparX Biopharmaceutical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SparX Biopharmaceutical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Mitsubishi Tanabe Pharma America

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            SparX Biopharma Signs Research Deal with Mitsubishi Tanabe for ADCs

                            Details : The SparX research with MTPA will focus on an ADC against a first-in-class immune cell target, with the potential to serve as a universal tumor-targeting strategy across multiple cancer types.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 15, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Mitsubishi Tanabe Pharma America

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SparX Biopharmaceutical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SparX Biopharmaceutical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPX-303

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SparX Doses First Patient with SPX-303, an anti-LILRB2/PD-L1 Bispecific Antibody

                            Details : SPX-303 is a bispecific antibody therapy targeting LILRB2 and PD-L1, under investigation for various solid tumors treatment.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 11, 2024

                            Lead Product(s) : SPX-303

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SparX Biopharmaceutical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SparX Biopharmaceutical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPX-303

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

                            Details : SPX-303 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 14, 2024

                            Lead Product(s) : SPX-303

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SparX Biopharmaceutical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SparX Biopharmaceutical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPX-303

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SparX Biopharmaceutical Announces FDA Greenlight for IND Application of SPX-303, A First-In-Human anti-LILRB2/...

                            Details : SPX-303 is a First-in-Its Class bispecific antibody therapy, ingeniously engineered to engage two cardinal immune checkpoint proteins, LILRB2 and PD-L1, simultaneously.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 30, 2023

                            Lead Product(s) : SPX-303

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SparX Biopharmaceutical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SparX Biopharmaceutical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPX-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Arovella Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            The SparX Group Enters into a Collaboration with Arovella Therapeutics for the Development of CLDN18.2-CAR-iNK...

                            Details : The collaboration aims for the utilization of SPX-101, an innovative monoclonal antibody (mAb) that targets the Claudin 18.2 (CLDN18.2) tumor specific antigen, as an exciting component in Arovella's CLDN18.2-CAR-iNKT cells as a leading off-the-shelf CAR-...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 10, 2023

                            Lead Product(s) : SPX-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Arovella Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SparX Biopharmaceutical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SparX Biopharmaceutical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPX-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors

                            Details : SPX-101 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 09, 2022

                            Lead Product(s) : SPX-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth